Phathom Pharmaceuticals, Inc. Form 8-K Summary
Business Context and Reporting Period
Phathom Pharmaceuticals, Inc. issued a Form 8-K under Item 2.02 on November 8, 2022, announcing financial results for the quarter ended September 30, 2022. The filing was signed on November 9, 2022. The company is a Delaware corporation headquartered in Florham Park, New Jersey, and its common stock trades on Nasdaq under the symbol PHAT.
Financial Metrics
The filing states that quarterly financial results were announced in an attached press release, but the provided filing text does not include the press release content or clear values for revenue, net income or loss, cash flow, margins, debt, cash, liquidity, or other financial metrics.
Material Changes Versus the Prior Comparable Period
The provided text does not describe changes versus the prior-year or prior-quarter comparable period.
Guidance, Outlook, Risks, and Unusual Items
No guidance, outlook, management commentary, risk disclosures, contingencies, or unusual items are included in the provided Form 8-K text. These matters may be addressed in Exhibit 99.1, the November 8, 2022 press release, which is referenced but not reproduced.
Key Facts to Verify
- Obtain and review Exhibit 99.1 for the complete third-quarter 2022 financial results.
- Verify reported revenue, operating expenses, net loss, cash and cash equivalents, cash used in operations, and any non-GAAP measures.
- Review management’s liquidity outlook, anticipated cash runway, development-program updates, and any forward-looking guidance.
- Confirm whether the company reported material debt, financing activity, contingencies, or other unusual items during the quarter.
- Note that the Form 8-K and Exhibit 99.1 are furnished under Item 2.02 and are not deemed filed for Exchange Act Section 18 liability purposes, except as expressly incorporated by reference.